Comparison of disease and risk classifications of AML before and after incorporation of NGS analysis of bone marrow samples.
Acute myeloid leukemia
International consensus classification
Next generation sequencing
Journal
International journal of hematology
ISSN: 1865-3774
Titre abrégé: Int J Hematol
Pays: Japan
ID NLM: 9111627
Informations de publication
Date de publication:
02 Sep 2024
02 Sep 2024
Historique:
received:
19
04
2024
accepted:
26
08
2024
revised:
13
08
2024
medline:
2
9
2024
pubmed:
2
9
2024
entrez:
2
9
2024
Statut:
aheadofprint
Résumé
Mutation profiling by next-generation sequencing (NGS) has facilitated understanding of the molecular pathogenesis of acute myeloid leukemia (AML), and has been incorporated into the new disease classification (International Consensus Classification; ICC) and risk classification (European LeukemiaNet [ELN] 2022; ELN2022). We compared disease subtypes between the previous disease classification (4th edition of the WHO classification; WHO-4) and the ICC in 91 patients with AML diagnosed at our institution. We also compared disease risk classifications using the previous risk classification (ELN2017) and the ELN2022. Targeted sequencing of bone marrow samples was conducted at Kyoto University. We found that entities under AML with recurrent genetic abnormalities were well-established, with almost no change from the WHO-4 to the ICC. In contrast, 16.7% of cases of AML, not otherwise specified in the WHO-4 were reclassified into AML with mutated TP53, and 36.7% were reclassified into AML with myelodysplasia-related gene mutations or cytogenetic abnormalities per the ICC. Meanwhile, the ELN2017 and ELN2022 showed no difference in concordance indexes in multivariate Cox regression analysis for progression-free and overall survival. The superiority of the ELN2022 over the ELN2017 could not be confirmed in our single-center retrospective study, and further investigation including multicenter prospective studies is needed.
Identifiants
pubmed: 39222234
doi: 10.1007/s12185-024-03841-w
pii: 10.1007/s12185-024-03841-w
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. Japanese Society of Hematology.
Références
Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, et al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140(11):1200–28. https://doi.org/10.1182/blood.2022015850 .
doi: 10.1182/blood.2022015850
pubmed: 35767897
pmcid: 9479031
Dohner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(12):1345–77. https://doi.org/10.1182/blood.2022016867 .
doi: 10.1182/blood.2022016867
pubmed: 35797463
Aparicio-Perez C, Prados de la Torre E, Sanchez-Garcia J, Martin-Calvo C, Martinez-Losada C, Casano-Sanchez J, et al. Evolving risk classifications in AML in a real-life scenario: after changes upon changes, is it more and more adverse? Cancers (Basel). 2023. https://doi.org/10.3390/cancers15051425 .
doi: 10.3390/cancers15051425
pubmed: 36900222
Lachowiez CA, Long N, Saultz J, Gandhi A, Newell LF, Hayes-Lattin B, et al. Comparison and validation of the 2022 European LeukemiaNet guidelines in acute myeloid leukemia. Blood Adv. 2023;7(9):1899–909. https://doi.org/10.1182/bloodadvances.2022009010 .
doi: 10.1182/bloodadvances.2022009010
pubmed: 36441905
Sargas C, Ayala R, Larrayoz MJ, Chillon MC, Rodriguez-Arboli E, Bilbao C, et al. Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group. Blood Cancer J. 2023;13(1):77. https://doi.org/10.1038/s41408-023-00835-5 .
doi: 10.1038/s41408-023-00835-5
pubmed: 37173322
pmcid: 10182047
World Health Organization. Classification of tumours of haematopoietic and lymphoid tissues. France: Lyon; 2008.
Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Buchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–47. https://doi.org/10.1182/blood-2016-08-733196 .
doi: 10.1182/blood-2016-08-733196
pubmed: 27895058
pmcid: 5291965
Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia. 2022;36(7):1703–19. https://doi.org/10.1038/s41375-022-01613-1 .
doi: 10.1038/s41375-022-01613-1
pubmed: 35732831
pmcid: 9252913
Rausch C, Rothenberg-Thurley M, Dufour A, Schneider S, Gittinger H, Sauerland C, et al. Validation and refinement of the 2022 European LeukemiaNet genetic risk stratification of acute myeloid leukemia. Leukemia. 2023;37(6):1234–44. https://doi.org/10.1038/s41375-023-01884-2 .
doi: 10.1038/s41375-023-01884-2
pubmed: 37041198
pmcid: 10244159
Jentzsch M, Bischof L, Ussmann J, Backhaus D, Brauer D, Metzeler KH, et al. Prognostic impact of the AML ELN2022 risk classification in patients undergoing allogeneic stem cell transplantation. Blood Cancer J. 2022;12(12):170. https://doi.org/10.1038/s41408-022-00764-9 .
doi: 10.1038/s41408-022-00764-9
pubmed: 36529759
pmcid: 9760726
Senapati J, Urrutia S, Loghavi S, Short NJ, Issa GC, Maiti A, et al. Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia. Blood. 2023;142(19):1647–57. https://doi.org/10.1182/blood.2023020649 .
doi: 10.1182/blood.2023020649
pubmed: 37441846